Our data show that the intravitreal levels of APOA2 and CP were inhibited in the vitreous humor of patients with PDR in response to IVC, suggesting that these proteins are involved in the development of diabetic retinopathy and that the mechanism of the effects of anti-VEGF treatment occurs via their effects on inflammation, apoptosis, and/or angiogenesis.
Importantly, the APOA2 and CP levels were altered and these proteins may be involved in the pathogenesis of PDR and the mechanism of anti-VEGF treatment.
Caption: Figure 5: Intravitreal level of (a) APOA2 and (b) ceruloplasmin measured by ELISA.
We investigated the effect of the -265T>C APOA2 polymorphism on fasting plasma lipids, lipoproteins, and particle size in both men and women.
The bioinformatic analysis of the APOA2 gene control (upstream) region indicates the potential for a CEBPA [CCAAT/enhancer binding protein (C/EBP) [alpha]] binding site that is not predicted with the minor C allele.
Since its discovery, APOA2 has been a protein in search of a function (29).
Despite the scarcity of previous data supporting a role of APOA2 in regulating food intake, copious experimental evidence demonstrates a pivotal role of another apolipoprotein, APOA4, as a satiety signal (20, 21, 39, 40).
As these effects were consistently found in both men and women, we suggest a new role for APOA2 in regulating food intake.
Sequence polymorphism at the human apolipoprotein All gene (APOA2): unexpected deficit of variation in an African-American sample.
 Nonstandard abbreviations: APOA2, apolipoprotein A-II; CVD, cardiovascular disease; GOLDN, Genetics of Lipid Lowering Drugs and Diet Network; BMI, body mass index; DHQ, diet history questionnaire; PUFA, polyunsaturated fat; SATFAT, saturated fat; IDL, intermediate-density lipoprotein; OR, odds ratio; MUFA, monounsaturated fat.